This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas. (BOLD 113)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02171260
Recruitment Status : Completed
First Posted : June 24, 2014
Last Update Posted : April 17, 2018
Children's Oncology Group
Information provided by (Responsible Party):
Eisai Inc.

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : April 17, 2015
  Actual Study Completion Date : January 28, 2016

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 June 18, 2018